Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells

Shuang En Chuang, Pei Yen Yeh, Yen Shen Lu, Gi Ming Lai, Chao Ming Liao, Ming Gao, Ann Lii Cheng

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Nuclear factor-κB (NF-κB) has been implicated in the development of drug resistance in cancer cells. We systematically examined the baseline levels of NF-κB activity of representative carcinoma cell lines, and the change of NF-κB activity in response to a challenge with four major anticancer drugs (doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel). We found that the basal level of NF-κB activity was heterogeneous and roughly correlated with drug resistance. When challenged with various drugs, all the cell lines examined responded with a transient activation of NF-κB which then declined to basal level despite variation in the concentration of the agent and the timing of the treatment. In contrast to tumor necrosis factor-α (TNF-α), which activates NF-κB in minutes, NF-κB activation induced by anticancer drugs usually occurred more than 1hr after stimulation. A gradual increase of total NF-κB and its nuclear translocation, and cytoplasmic translocation of nuclear IκBα and its degradation were involved in this process. In particular, when cells were pretreated with common biologic modulators such as tamoxifen, dexamethasone, and curcumin, the doxorubicin-induced NF-κB activation was attenuated significantly. This inhibition may play a role in sensitizing cancer cells to chemotherapeutic drugs. This study has demonstrated that activation of NF-κB is a general cellular response to anticancer drugs, and the mechanism of activation appears to be distinct from that induced by TNF-α. These observations may have implications for improving the efficacy of systemic chemotherapy for cancer patients.

Original languageEnglish
Pages (from-to)1709-1716
Number of pages8
JournalBiochemical Pharmacology
Volume63
Issue number9
DOIs
Publication statusPublished - May 1 2002
Externally publishedYes

Fingerprint

Curcumin
Tamoxifen
Dexamethasone
Chemical activation
Cells
Carcinoma
Drug Resistance
Pharmaceutical Preparations
Doxorubicin
Tumor Necrosis Factor-alpha
Cell Line
Neoplasms
Fluorouracil
Chemotherapy
Drug Therapy
Paclitaxel
Metabolic Activation
Modulators
Cisplatin
Degradation

Keywords

  • Curcumin
  • Drug resistance
  • NF-κB
  • Steroid
  • Tamoxifen
  • TPA

ASJC Scopus subject areas

  • Pharmacology

Cite this

Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. / Chuang, Shuang En; Yeh, Pei Yen; Lu, Yen Shen; Lai, Gi Ming; Liao, Chao Ming; Gao, Ming; Cheng, Ann Lii.

In: Biochemical Pharmacology, Vol. 63, No. 9, 01.05.2002, p. 1709-1716.

Research output: Contribution to journalArticle

@article{0b3c7bc0c35b4e0ca93de2fe749b04a9,
title = "Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells",
abstract = "Nuclear factor-κB (NF-κB) has been implicated in the development of drug resistance in cancer cells. We systematically examined the baseline levels of NF-κB activity of representative carcinoma cell lines, and the change of NF-κB activity in response to a challenge with four major anticancer drugs (doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel). We found that the basal level of NF-κB activity was heterogeneous and roughly correlated with drug resistance. When challenged with various drugs, all the cell lines examined responded with a transient activation of NF-κB which then declined to basal level despite variation in the concentration of the agent and the timing of the treatment. In contrast to tumor necrosis factor-α (TNF-α), which activates NF-κB in minutes, NF-κB activation induced by anticancer drugs usually occurred more than 1hr after stimulation. A gradual increase of total NF-κB and its nuclear translocation, and cytoplasmic translocation of nuclear IκBα and its degradation were involved in this process. In particular, when cells were pretreated with common biologic modulators such as tamoxifen, dexamethasone, and curcumin, the doxorubicin-induced NF-κB activation was attenuated significantly. This inhibition may play a role in sensitizing cancer cells to chemotherapeutic drugs. This study has demonstrated that activation of NF-κB is a general cellular response to anticancer drugs, and the mechanism of activation appears to be distinct from that induced by TNF-α. These observations may have implications for improving the efficacy of systemic chemotherapy for cancer patients.",
keywords = "Curcumin, Drug resistance, NF-κB, Steroid, Tamoxifen, TPA",
author = "Chuang, {Shuang En} and Yeh, {Pei Yen} and Lu, {Yen Shen} and Lai, {Gi Ming} and Liao, {Chao Ming} and Ming Gao and Cheng, {Ann Lii}",
year = "2002",
month = "5",
day = "1",
doi = "10.1016/S0006-2952(02)00931-0",
language = "English",
volume = "63",
pages = "1709--1716",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells

AU - Chuang, Shuang En

AU - Yeh, Pei Yen

AU - Lu, Yen Shen

AU - Lai, Gi Ming

AU - Liao, Chao Ming

AU - Gao, Ming

AU - Cheng, Ann Lii

PY - 2002/5/1

Y1 - 2002/5/1

N2 - Nuclear factor-κB (NF-κB) has been implicated in the development of drug resistance in cancer cells. We systematically examined the baseline levels of NF-κB activity of representative carcinoma cell lines, and the change of NF-κB activity in response to a challenge with four major anticancer drugs (doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel). We found that the basal level of NF-κB activity was heterogeneous and roughly correlated with drug resistance. When challenged with various drugs, all the cell lines examined responded with a transient activation of NF-κB which then declined to basal level despite variation in the concentration of the agent and the timing of the treatment. In contrast to tumor necrosis factor-α (TNF-α), which activates NF-κB in minutes, NF-κB activation induced by anticancer drugs usually occurred more than 1hr after stimulation. A gradual increase of total NF-κB and its nuclear translocation, and cytoplasmic translocation of nuclear IκBα and its degradation were involved in this process. In particular, when cells were pretreated with common biologic modulators such as tamoxifen, dexamethasone, and curcumin, the doxorubicin-induced NF-κB activation was attenuated significantly. This inhibition may play a role in sensitizing cancer cells to chemotherapeutic drugs. This study has demonstrated that activation of NF-κB is a general cellular response to anticancer drugs, and the mechanism of activation appears to be distinct from that induced by TNF-α. These observations may have implications for improving the efficacy of systemic chemotherapy for cancer patients.

AB - Nuclear factor-κB (NF-κB) has been implicated in the development of drug resistance in cancer cells. We systematically examined the baseline levels of NF-κB activity of representative carcinoma cell lines, and the change of NF-κB activity in response to a challenge with four major anticancer drugs (doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel). We found that the basal level of NF-κB activity was heterogeneous and roughly correlated with drug resistance. When challenged with various drugs, all the cell lines examined responded with a transient activation of NF-κB which then declined to basal level despite variation in the concentration of the agent and the timing of the treatment. In contrast to tumor necrosis factor-α (TNF-α), which activates NF-κB in minutes, NF-κB activation induced by anticancer drugs usually occurred more than 1hr after stimulation. A gradual increase of total NF-κB and its nuclear translocation, and cytoplasmic translocation of nuclear IκBα and its degradation were involved in this process. In particular, when cells were pretreated with common biologic modulators such as tamoxifen, dexamethasone, and curcumin, the doxorubicin-induced NF-κB activation was attenuated significantly. This inhibition may play a role in sensitizing cancer cells to chemotherapeutic drugs. This study has demonstrated that activation of NF-κB is a general cellular response to anticancer drugs, and the mechanism of activation appears to be distinct from that induced by TNF-α. These observations may have implications for improving the efficacy of systemic chemotherapy for cancer patients.

KW - Curcumin

KW - Drug resistance

KW - NF-κB

KW - Steroid

KW - Tamoxifen

KW - TPA

UR - http://www.scopus.com/inward/record.url?scp=0036569563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036569563&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(02)00931-0

DO - 10.1016/S0006-2952(02)00931-0

M3 - Article

C2 - 12007574

AN - SCOPUS:0036569563

VL - 63

SP - 1709

EP - 1716

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 9

ER -